Oncotelic Therapeutics (OTLC) CEO Vuong Trieu Buys $5.8K of Stock
On June 24, 2026, CEO Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
Vuong Trieu, CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. ($OTLC), bought 115,000 shares at an average price of $0.05, worth about $5,750, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OTLC is up 0.0% after 1 week, up 0.0% after 1 month and down 50.0% to date (from the $0.04 close on Jun 24, 2026).
OTLC
Oncotelic Therapeutics, Inc.
Key Points
- On June 24, 2026, Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, bought 115,000 shares at $0.05 each.
- Shares of Oncotelic Therapeutics traded near $0.04 on Thursday, with a market cap of about $22.2 million.
- Recent insider buying includes multiple purchases by Trieu and CFO Amit Shah, reflecting ongoing interest in the company.
Get $OTLC trade alerts by text
We text you when insiders, Congress or big funds trade $OTLC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Oncotelic Therapeutics, Inc. alert may contain errors. Disclosures
On June 24, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), bought 115,000 shares of the company. The shares were purchased at an average price of $0.05, totaling about $5,750. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
In addition to the recent purchase on June 24, Vuong Trieu has been actively buying shares throughout June. On June 23, he acquired 75,000 shares, and on June 22, he bought another 65,000 shares, both at $0.05 per share. Earlier, on June 17, Trieu purchased 239,759 shares at $0.04 per share. The company's CFO, Amit Shah, also bought 20,000 shares at $0.05 on June 22.
Oncotelic Therapeutics, Inc. Stock Up 100.0%
Shares of Oncotelic Therapeutics traded near $0.04 on Thursday. The company has a market capitalization of approximately $22.2 million. Its P/E ratio is notably low at 0.08, indicating a very low earnings multiple. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company's beta is -0.317, suggesting it might be less volatile than the market.
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. is a biopharmaceutical company based in Agoura Hills, California. The company focuses on developing treatments for rare cancer types. It works on antisense and small molecule injectable drugs for cancer treatment. Oncotelic is also developing drugs for acute myeloid leukemia, pancreatic cancer, and other conditions. Led by Dr. Vuong Trieu, the company employs 38 people and is involved in innovative drug development to address unmet medical needs.
Bottom Line
Vuong Trieu's recent share purchases highlight his confidence in Oncotelic Therapeutics' future. Investors often watch insider buying as a potential indicator of a company's prospects. However, it's important to remember that these transactions are disclosed after they occur and may not reflect the current state of the company's stock. As always, due diligence is crucial when considering any investment.
Related Filing Alerts
Source: Vuong Trieu's Form 4 filing on $OTLC (Jun 24, 2026). Find the original filing: OTLC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts